The Internet Journal of Dermatology最新文献

{"title":"Erythromelalgia and psoriasis","authors":"M. Hanabusa, D. Tsuruta, M. Ishii, Hiromi Kobayashi","doi":"10.5580/145c","DOIUrl":"https://doi.org/10.5580/145c","url":null,"abstract":"Psoriasis is a common, chronic devastating skin disease. Erythromelalgia is a rare disease characterized by episodic attacks of burning pain and inflammatory vasodilation in the distal extremities, especially after increased temperature. We are reporting 66year-old Japanese man diagnosed as erythromelalgia secondary to psoriasis. Although intravenous lidocaine, ketamine and oral steroid did not control his lesions and pain, low-dose aspirin successfully improved his pain. In addition, psoriatic macules were also dramatically healed at the same time. Low-dose aspirin is an old drug for the treatment of psoriasis, but still usable.","PeriodicalId":161194,"journal":{"name":"The Internet Journal of Dermatology","volume":"70 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2008-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115064598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CD4 T-Cell Cytokine Response to Mite Recombinant Tropomyosin in Mite, Snail and Shrimp Allergic Patients","authors":"L. Martins, E. Pires, F. Inácio","doi":"10.5580/194c","DOIUrl":"https://doi.org/10.5580/194c","url":null,"abstract":"Allergies to snails and mites are definitely linked. Snail allergens have been already identified and there is no evidence of crossreaction between snail and mite tropomyosin. This work is a preliminary study on immune cell function, evaluating possible tropomyosin-triggering in a snail-mite-shrimp cross-reaction. Peripheral blood mononuclear cells from 6 different phenotype patients in relation to snails, mites and crustaceans, were cultured with mite recombinant tropomyosin (rDer p 10), anti-CD28 and brefeldin A. Phytohemagglutinin mitogen was used as a positive control. CD4 T-cell response was evaluated towards CD69, IFN-γ, IL-2, IL-4, IL-5 and IL-13, in flow cytometry. rDer p 10 induced different cytokine expression in the six phenotypes. Allergen-specific IFN-γ stimulation was suggested by an increase in IFN-γ, IL-5, and IL-13 only in allergic to crustaceans, with a dose-dependent effect on IL-5 and IL-13. Tropomyosin is probably the main allergen responsible for the mite-shrimp crossreactivity but may not play a major role in snail-mite-shrimp cross-reactions. This work was done in the Laboratory of Immunology from Hospital de S. Bernardo, Setubal, Portugal.","PeriodicalId":161194,"journal":{"name":"The Internet Journal of Dermatology","volume":"59 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2008-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114570059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mastocytosis, Melanoma And Sarcoidosis","authors":"M. Lee-Wong, M. Laufer, M. Karagic","doi":"10.5580/15a1","DOIUrl":"https://doi.org/10.5580/15a1","url":null,"abstract":"This report describes a 30-year-old man with a history of malignant melanoma who developed various signs, symptoms and laboratory findings which were consistent with systemic mastocytosis. The patient also developed night sweats, weight loss and dyspnea, along with bilateral hilar lymphadenopathy and diffuse pulmonary infiltrates. A transbronchial biopsy revealed nonnecrotizing granulomas that were diagnosed as sarcoidosis. We believe this is the first report of melanoma and mastocytosis in the same patient, suggesting a possible genetic link between the two diseases. The pulmonary manifestations were ultimately found to be due to sarcoidosis.","PeriodicalId":161194,"journal":{"name":"The Internet Journal of Dermatology","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2008-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122076173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Cutaneous CD30+ Anaplastic Large Cell Lymphoma (ALCL) with Worse Outcome: Presentation with Extensive Limb Disease (ELD)","authors":"Youn H Kim","doi":"10.5580/10ed","DOIUrl":"https://doi.org/10.5580/10ed","url":null,"abstract":"Youn H. Kim, M.D. is the Joanne and Peter Haas Jr. Professor for Cutaneous Lymphoma Research in the Department of Dermatology at Stanford University School of Medicine. She is a member of the Stanford Cancer Center and Director of the Multidisciplinary Cutaneous Lymphoma Clinic and Program at Stanford. She is a member of the NonHodgkin’s Lymphoma Panel of the National Comprehensive Cancer Network and serves on the Advisory Board of the international Society for Cutaneous Lymphomas, the Board of Directors of the US Consortium for Cutaneous Lymphomas, and the Board of Directors of the Medical Dermatology Society. She is an elected member of the American Dermatologic Association, member of the American Society of Hematology, the American Academy of Dermatology, and the Society for Investigative Dermatology.","PeriodicalId":161194,"journal":{"name":"The Internet Journal of Dermatology","volume":"2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2008-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129930001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy And Safety Evaluation Of A Dry Powder Inhaler Containing Salmeterol Xinafoate 25 Mcg/Fluticasone Propionate 250 Mcg In Subjects With Asthma: A Randomized, Open Label, Comparative, Active Controlled, Parallel Groups, And Multi-Centric Study.","authors":"S. Bardapurkar, H. Dumra, V. Karkhanis, V. Chandarana, Amir M. Khoja, N. Prasad, R. Bhagat, Ajay Keni, Nitin Joshi B. Pharm Mumbai, Shravanti Bhowmik M.D. Mumbai","doi":"10.5580/22b1","DOIUrl":"https://doi.org/10.5580/22b1","url":null,"abstract":"Background: Dry powder inhalers have now an established role in inhalation therapy with wide variation in design characteristics impacting their suitability for use in different patient populations. SPARC device structure enables higher amount of the inhaled drug to be delivered to lungs, making possible a reduction in administered dose. Objective: This study was planned to compare efficacy and safety of SPARC device containing Salmeterol 25 mcg/Fluticasone Propionate 250 mcg with Seretide Accuhaler (GSK) containing Salmeterol 50 mcg/Fluticasone Propionate 500 mcg. Methods: This was a 4-week, randomized, open-label, active-controlled, multicenter study (N= 113) of patients aged 1860 years with asthma, reversible bronchial obstruction, and FEV1 4080% of the predicted normal. After washout from ongoing asthma treatments, there was a 2-week run-in period when patients were permitted use of rescue medication (Salbutamol metered dose inhaler). Patients who successfully competed the run-in period with FEV1 4080% of the predicted normal were randomized 1:1 to SPARC device or Seretide Accuhaler ® for a 4week treatment period. Patients received twice daily inhalation between 8.00 a.m. to 10.00 a.m. and between 8.00 p.m. to 10.00 p.m. with approximately 12 hour interval between the two doses.Results: The improvements in SPARC device group (S/FP 25/250 mcg) were similar to Seretide Accuhaler group (S/FP 50/500 mcg). The FEV1 increased by 9.73% of predicted normal value in test group and 7.82% in reference group after 4-weeks of treatment. Although the S/FP 25/250 mcg group showed a trend towards more improvement than S/FP 50/500 mcg group in evening peak expiratory flow rate, all differences in subjective and objective outcome measures were not statistically significant. None of the safety measures included in this study showed important clinical differences between treatments. Conclusion: Administered at half the dose of Seretide Accuhaler, the efficacy of Sun device is not statistically significantly different on efficacy parameters evaluated.","PeriodicalId":161194,"journal":{"name":"The Internet Journal of Dermatology","volume":"55 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2008-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130119957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vorinostat in Combination Therapy of Sézary Syndrome with Extracorporeal Photopheresis","authors":"O. Akilov, L. Geskin","doi":"10.5580/c07","DOIUrl":"https://doi.org/10.5580/c07","url":null,"abstract":"Vorinostat, the first in its class of orally administered histone deacetylase inhibitors, was recently FDA-approved for therapy of skin manifestations of cutaneous T cell lymphoma. Vorinostat monotherapy demonstrated activity in patients with CTCL in clinical trials with an overall response rate of 30%. The combination of vorinostat with other agents or treatment modalities has not been formally evaluated. We hypothesized that the use of vorinostat in combination with extracorporeal photopheresis might be of benefit, theoretically through further induction of cell cycle arrest and apoptosis of malignant T lymphocytes. We present a case report of a patient with refractory Sezary syndrome who responded well to this combination without significant or unexpected side effects. Dr. Larisa Geskin, MD, FAAD is an Assistant Professor of Dermatology at the Department of Dermatology, University of Pittsburgh School of Medicine. Dr. Geskin serves as the Director of the Dermatological Branch of University of Pittsburgh Cancer Institute Multidisciplinary Melanoma Center, the Cutaneous Oncology and Photopheresis Center at the University of Pittsburgh Medical Center. She also is Director of the Dermatology Residency Program at the University of Pittsburgh Medical School. Dr. Larisa Geskin’s broad research interests include exploring etiology of CTCL and abnormalities found in malignant cells of patients with CTCL. Her main focus is to investigate and define immunologic abnormalities found in patients with CTCL and to develop novel immunologic therapies for CTCL. She conducts numerous clinical trials investigating new treatments for CTCL, including a dendritic cell vaccine trial for patients with Sezary syndrome.","PeriodicalId":161194,"journal":{"name":"The Internet Journal of Dermatology","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2008-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134174004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequency of skin diseases among sea fishermen in Basrah","authors":"K. Hamdi, Mohsin A. Al-Malikey","doi":"10.5580/16f6","DOIUrl":"https://doi.org/10.5580/16f6","url":null,"abstract":"The sea represents part of the southern border of Basrah. Working in and dealing with the sea water, mainly fishing, is the occupation of many Basrah citizens, where a number of them are attending the out patient clinic of Dermatology and Venereology at the Basrah Teaching Hospital suffering from skin diseases. Objectives: The objectiv of the present work is to evaluate the frequency of skin diseases among sea fishermen in Basrah. Patients and Methods: This is a case-control epidemiological study in which 230 sea fishermen have been collected from the fishing boats harbor (AlNagaah) at Al-Fao city during the period between May 2006 through July 2007. All of them were males and their ages were ranging from 12-72 years with a mean±SD 28.60±11.88. Two hundred thirty subjects attending the outpatient clinic of the general hospital of the same city, as companions of the patients, were enrolled in this study as a control group. They were of comparable age, sex, and season. Fishermen were excluded. Results: The study showed that marine stings (including jellyfish stings, seabather's eruption, stingray and stonefish stings) were specific for sea fishermen in comparison with control 48 (20.9%) Vs. 0, the frequency of other skin diseases were higher and achieved a statistical significance among sea fishermen in comparison with control group in the following skin diseases:, bacterial infection 35 (15.2%) Vs. 9 (3.9% ) , fungal infection 79 (34.3%) Vs.46 (20%), warts 25(10.9%) Vs. 9 (3.9%), sunburn 35 (15.2%) Vs. 13 (5.7%), facial wrinkling 9 (34.3) Vs.52 (22.6%), lentigens and freckles 36(15.7%) Vs .15 (6.5%), contact dermatitis 25(10.9%) Vs. 7(3%), palmer hyperkeratosis 130 (56.5%) Vs.43 (18.7%), miliaria 58 (25.2%) Vs.30 (13%) respectively. Some other skin diseases were also higher but did not reach a statistical significance: melasma , actinic chelitis, cutis rhomboidalis nuchae and chilblain; the other skin diseases were not different like cholinergic urticaria, seborrhoeic dermatitis and discoid lupus erythematosus. Conclusion: The present work showed that fishing in the sea is a hazardous occupation in which the fishermen are liable for different skin diseases caused by their hard working environment, so that dermatologists working in this area should be familiar with these diseases.","PeriodicalId":161194,"journal":{"name":"The Internet Journal of Dermatology","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2008-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117206258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Mycosis Fungoides","authors":"S. Lessin","doi":"10.5580/13c0","DOIUrl":"https://doi.org/10.5580/13c0","url":null,"abstract":"Stuart R. Lessin M.D. is an investigative dermatologist with a research and clinical interest in cutaneous oncology. He has investigated the etiologic role of oncogenic viruses in cutaneous T cell lymphoma (CTCL) and the molecular mechanisms underlying oncogene and tumor suppressor gene expression in development and tumor progression of CTCL. He has developed techniques for the molecular diagnosis of lymphoproliferative skin diseases based on Tcell receptor (TCR) gene expression. Since 2000, Dr. Lessin has served as Director of Dermatology at the Fox Chase Cancer Center (FCCC) in","PeriodicalId":161194,"journal":{"name":"The Internet Journal of Dermatology","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2008-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123294676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stage IIB Mycosis Fungoides","authors":"S. Daulat, M. Duvic, S. Daulat","doi":"10.5580/2593","DOIUrl":"https://doi.org/10.5580/2593","url":null,"abstract":"Seema Daulat is from Dallas, Texas and completed her undergraduate studies in Finance and Spanish at the University of Texas at Austin. She then obtained her MD from University of Texas Southwestern Medical School in Dallas. She completed a preliminary internship in Internal Medicine at the University of Washington in Seattle. She is currently a dermatology clinical research fellow studying cutaneous T-cell lymphoma under Madeleine Duvic at MD Anderson Cancer Center in Houston, Texas.","PeriodicalId":161194,"journal":{"name":"The Internet Journal of Dermatology","volume":"51 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2008-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121447145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lupus And Lipstick: The Industry Responds","authors":"Kenneth Masters","doi":"10.5580/2748","DOIUrl":"https://doi.org/10.5580/2748","url":null,"abstract":"Introduction: Evidence links lipstick to systemic lupus erythematosus (SLE). This study aims at obtaining a response from the lipstick industry. Method: A 4-item electronic and postal survey, with 2 follow-up mailings, was conducted amongst 19 major lipstick companies. Results: From the electronic survey, 100% of the companies responded with machine-generated confirmations of receipt. Human responses were obtained from 10 of the companies. The responses were characterized by refusal to participate, referrals to non-responsive contact details, and standard disclaimers. Only 1 company answered the questions directly, and 1 indirectly. Discussion and conclusion: Despite the lipstick industry's awareness of the research, there appears to be little concern over the link between lipstick and SLE. There is the need for the lipstick industry to research the link, for the medical fraternity to adjust acceptable guidelines, and for the impact of lipstick transfer, particularly to children and infants, to be researched. INTRODUCTION Since 1969 [1], there has been a suggested link between the use of lipstick and the onset of systemic lupus erythematosus (SLE). More recently, Wang et al indicated that “Using lipstick at least 3 days/week was significantly associated with increased risk of SLE” [2]. Studies consistently report that 80% to 90% of all SLE patients are women, half of whom first present symptoms between the age of 15 and 30 [3,4,5,6,7]. It is difficult to know the percentage of women who wear lipstick, but, in Western Countries, the figure appears to be at least 50% [2,8,9] with some estimates of 98% of women in the USA between the ages of 18 and 34 [10], and popular press estimates ranging from 70% to 90% [11,12]. Given this information, there is surely a need for a response to the work of Burry and Wang et al from lipstick manufacturers. The aim of this study was to learn the extent to which the cosmetic companies are aware of this research, and their responses to such research.","PeriodicalId":161194,"journal":{"name":"The Internet Journal of Dermatology","volume":"142 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2008-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122408093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}